Get the Stockscreener App
0.5863
2.29%
0.0131
Sangamo Therapeutics Inc stock is traded at $0.5863, with a volume of 5.09M.
It is up +2.29% in the last 24 hours and up +22.20% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.5732
Open:
$0.5839
24h Volume:
5.09M
Relative Volume:
0.93
Market Cap:
$176.89M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.7817
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
+1.09%
1M Performance:
+22.20%
6M Performance:
-45.21%
1Y Performance:
-31.81%
1-Day Range:
$0.57
$0.6049
1-Week Range:
$0.5321
$0.6049
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5863 | 177.74M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Predicting Sangamo Therapeutics Inc. trend using moving averages2025 Trading Volume Trends & Safe Entry Zone Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Market Volume Report & Scalable Portfolio Growth Ideas - Newser
Long term hold vs stop loss in Sangamo Therapeutics Inc.Quarterly Profit Review & Real-Time Stock Entry Alerts - Newser
Will Sangamo Therapeutics Inc. stock recover after recent dropBuy Signal & Free Daily Entry Point Trade Alerts - Newser
Sangamo Therapeutics Inc. stock prediction for this weekJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Will Sangamo Therapeutics Inc. outperform the marketJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Custom strategy builders for tracking Sangamo Therapeutics Inc.July 2025 Market Mood & Precise Entry and Exit Recommendations - Newser
Risk adjusted return profile for Sangamo Therapeutics Inc. analyzed2025 Bull vs Bear & Reliable Price Breakout Signals - Newser
Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to “Hold” - Defense World
HC Wainwright Analysts Raise Earnings Estimates for SGMO - Defense World
How Sangamo Therapeutics Inc. stock performs during market volatilityQuarterly Market Summary & Verified Swing Trading Watchlist - Newser
Sangamo rises after trial data for Fabry disease therapy - MSN
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
What Makes Sangamo (SGMO) a New Buy Stock - sharewise.com
Analyzing Sangamo Therapeutics (NASDAQ:SGMO) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Has Sangamo Therapeutics Inc. formed a bullish divergence2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
What to expect from Sangamo Therapeutics Inc. in the next 30 daysWeekly Profit Report & Weekly Consistent Profit Watchlists - Newser
Sangamo Therapeutics (SGMO.O) Surges 11.3% on Strong KDJ Signal Amid Mixed Biotech Sector Moves - AInvest
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSwing Gain Strategy with Entry Forecast - Newser
Sangamo Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates - MSN
Will Sangamo Therapeutics Inc. rebound enough to break evenJuly 2025 Pullbacks & Safe Entry Point Identification - Newser
Transcript : Sangamo Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sangamo: Q2 Earnings Snapshot - Greenwich Time
Earnings call transcript: Sangamo Therapeutics Q2 2025 earnings miss, stock drops - Investing.com Australia
Sangamo Q2 2025 slides: Neurology pipeline advances amid financial challenges - Investing.com Australia
Sangamo Therapeutics shares fall 4.55% premarket after Q2 revenue misses estimates. - AInvest
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics 2025 Q2 Earnings Improved Losses Despite Revenue Surge - AInvest
Sangamo Therapeutics Reports Strong Q2 2025 Results - TipRanks
Sangamo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sangamo Therapeutics Q2 Misses Revenue Estimates and Reiterates 2025 Guidance — What This Means for Its Strategic Path Forward - AInvest
Sangamo Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Sangamo Therapeutics Q2 revenue misses estimates - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - Yahoo Finance
Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Thursday - Defense World
Sangamo Therapeutics Announces Second Quarter 2025 Earnings CallLife Science Industry News - Zenopa
GSA Capital Partners LLP Boosts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedHigh-yield market plays - Jammu Links News
What are Sangamo Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
How does Sangamo Therapeutics Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
Why is Sangamo Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on top-performing stocks - Jammu Links News
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):